AUBONNE, Switzerland, March 28, 2019 / PRNewswire / – Merck, a modern science and technology company, today announced the funding of 150 million euros (165 million francs) for a Swiss production site. Aubonne, to maximize his production capacity for biotechnology products.
The investment involves the Merck biotechnology facility for over 150 countries to help meet the growing patient needs of major drugs as a treatment since Gonal-f fertility production. T®, recently used for market treatments, such as the drug against Bavencio cancer t®or for future substances which may be present under clinical development as being treated against cancer M7824 (alpha * bintrafusp).
“This investment demonstrates our commitment to ensuring that our medicines consistently meet the highest standards and are always available to patients throughout the world. When they need them, ”said Belén Garijo, a member of the World Health Organization Executive Board. Merck and President and Chief Executive of Merck Healthcare (Healthcare) worldwide. “This investment is investing in the future growth of our Healthcare industry. "
“With this latest investment, Merck will defend a strong position in canton de Vaud as it is now Glen Health, which already includes 360 companies and 400 laboratories representing 20,000 jobs, "said more Philippe Leuba, State Consultant of Canton Vaud. “Merck's presence in canton of Vaud is highly valued and this new investment will have a positive positive impact on the sector. "
The building will be equipped with state-of-the-art aseptic and quality control technologies, with innovative design and a flexible outcome model that will allow performance. The aeptic biomedical network lines are equipped with loneliness, the technology that is best demonstrated in aseptic filling to ensure drugs are safely prevented. One line is defined on formulas at the freezing frost and the other for beer formulas. These two new lines in addition to the new quality control tests will replace the current facilities, ensuring that there is technological development and an increase in up to 27 million bottles each year.
The new building should be completed by 2020, this should include the new quality control tests 2021 and the new aseptic transmission lines in 2023, following approval by the regulatory authorities. All are designed to achieve the highest international standards in quality, environment, health and safety.
With the Aubonne site and the site nearby Vevey, Switzerland has a key role in making Merck bio-medical treatments. Merck has spent more than one billion Swiss francs (800 million euros) spent in Switzerland over the last ten years, reflecting the country's strategic importance where the company employs 2,300 people at 11 sites. . Aubonne Sites and Vevey they are part of a global network of 18 sites aimed at Merck's biomass products and medicines, serving 70 million patients every day around the world.
* Bintrafusp alfa is the international non-validated name (INN) recommended for two-point immune protection M7824. Alpha antibiotics are currently undergoing a clinical assessment and practice is not permitted anywhere in the world.
All press releases are distributed by email at the same time as being available on Merck's website. Please go to www.merckgroup.com/subscribe to register online, change your choice or stop this service.
Merck is a leading science and technology company active in Healthcare, Life Science and High Achievement Materials. Around 52,000 staff will work to have a positive impact on the lives of millions of people each day giving them a better and more sustainable quality of life. The company everywhere – from the development of genetic modification technologies, to finding out about specific ways to tackle the most complex diseases, to the development of intelligent devices. In 2018 Merck created an estimated 14.8 billion euros in 66 countries.
Scientific research and entrepreneurship is responsible for contributing to Merck's technological and scientific advances. These factors are a key attribute of Merck since its establishment in 1668. The family is kept by most of the commercial company. Merck has great rights for the name Merck and the trademark, except the United States of America and the United States Canada, the Merck business sectors work as EMD Serono for Healthcare, MilliporeSigma for Life Sciences and EMD for High Performance Materials.
Phone. : 41 79 500 01 37